Mouth spray may soothe painful sores from cancer radiation

NCT ID NCT07467759

Completed Symptom relief Sponsor: Tishreen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a benzydamine hydrochloride (Difflam) oral spray can reduce the severity of mouth sores caused by high-dose radiation in head and neck cancer patients. Thirty-five adults receiving radiation without chemotherapy were randomly assigned to standard mouth care or standard care plus the spray for six weeks. Researchers tracked soreness weekly using a standard scale to see if the spray helped.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: benzydamine hydrochloride (Difflam) oral spray
What this could lead to: If it works, this spray could become a standard way to reduce painful mouth sores during radiation therapy for head and neck cancer.
What could go wrong: This is a small, single-center trial with only 35 participants, so results may not apply to everyone. The spray may not work better than standard care alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced oral mucositis head and neck cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RADIATION INDUCED ORAL MUCOSITIS

Contacts and locations

Locations

Pharmacy, Latakia university

Latakia, Syria

More trials for these conditions

Other studies related to the condition(s) this trial covers.